{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:53Z","timestamp":1792622633622,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11060-020-03687-2","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T17:04:29Z","timestamp":1610211869000},"page":"135-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-5259","authenticated-orcid":false,"given":"Takahisa","family":"Mikami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Green-LaRoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Jeyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"3687_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"3687_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"3687_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"3687_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22:709\u2013718. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"3687_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ et al (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6:1\u20136. https:\/\/doi.org\/10.1186\/s40425-018-0393-z","journal-title":"J Immunother Cancer"},{"key":"3687_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:1\u20139. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"3687_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"key":"3687_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24:435\u2013443. https:\/\/doi.org\/10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"3687_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","volume":"39","author":"H-H Ji","year":"2019","unstructured":"Ji H-H, Tang XW, Dong Z et al (2019) Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig 39:319\u2013330. https:\/\/doi.org\/10.1007\/s40261-018-0735-0","journal-title":"Clin Drug Investig"},{"key":"3687_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/diagnostics8040076","volume":"8","author":"TG Soldatos","year":"2018","unstructured":"Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L et al (2018) Retrospective side effect profiling of the metastatic melanoma combination therapy ipilimumab-nivolumab using adverse event data. Diagnostics 8:76. https:\/\/doi.org\/10.3390\/diagnostics8040076","journal-title":"Diagnostics"},{"key":"3687_CR11","unstructured":"US Food and Drug Administration (FDA) (2012) Code of federal regulations title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32. Accessed 8 May 2020"},{"key":"3687_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"3687_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"3687_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M et al (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28:377\u2013385. https:\/\/doi.org\/10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"key":"3687_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"3687_CR16","doi-asserted-by":"crossref","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11","DOI":"10.1177\/1756286418799864"},{"key":"3687_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J et al (2017) Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36\u201349. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat Rev"},{"key":"3687_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neuro-Oncol 145:1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neuro-Oncol"},{"key":"3687_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"3687_CR20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","volume":"17","author":"LC Kennedy","year":"2019","unstructured":"Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. JNCCN J Natl Compr Cancer Netw 17:750\u2013757. https:\/\/doi.org\/10.6004\/jnccn.2019.7310","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"3687_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"3687_CR22","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","volume":"17","author":"W Wick","year":"2016","unstructured":"Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17:e529\u2013e541. https:\/\/doi.org\/10.1016\/S1470-2045(16)30571-X","journal-title":"Lancet Oncol"},{"key":"3687_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18:1\u20139. https:\/\/doi.org\/10.1007\/s11910-018-0878-7","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-020-03687-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T03:26:26Z","timestamp":1614309986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-020-03687-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3687"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03687-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"25 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there are no conflicts of interest relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}